Participate in Research for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Learn about clinical trials looking at a potential therapy to address mutations in the plakophilin 2 (PKP2) gene, the leading genetic cause of ARVC.
A Phase 1b clinical trial of an investigational gene therapy called TN-401 for the treatment of ARVC caused by mutations in the PKP2 gene. All participants in this trial will receive the investigational gene therapy.
An antibody testing and natural history study designed to learn about who might be eligible for and benefit from an AAV-based gene therapy such as TN-401. No investigational treatments are given in this study.
About Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
ARVC affects how heart cells are connected and communicate with each other. In a person with ARVC, heart cells lose their structure over time and this can lead to heart failure. The heart cells may also lose their ability to communicate, causing irregular heart rhythms, called arrhythmias, which can lead to sudden cardiac arrest.
Gene Therapy for ARVC
By delivering a working gene to heart muscle cells, gene therapy has the potential to correct the underlying cause of genetic heart conditions, like ARVC.
Contact Us
For more information about taking part in research for ARVC due to PKP2 mutation, complete this form or contact our Patient Advocacy team by email at patient.advocacy@tenayathera.com or phone at (650) 825-6990 option 4.
